MA27250A1 - Formulations de fibrate en nano-particules - Google Patents
Formulations de fibrate en nano-particulesInfo
- Publication number
- MA27250A1 MA27250A1 MA27964A MA27964A MA27250A1 MA 27250 A1 MA27250 A1 MA 27250A1 MA 27964 A MA27964 A MA 27964A MA 27964 A MA27964 A MA 27964A MA 27250 A1 MA27250 A1 MA 27250A1
- Authority
- MA
- Morocco
- Prior art keywords
- particles
- nano
- fibrate
- fibrate formulations
- fasted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
La présente invention concerne des compositions de fibrate ayant des profils pharmacocinétiques améliorés ainsi qu'une variabilité réduite en fonction de l'état non à jeun ou à jeun. Les particules de fibrate de la composition présentent une granulometrie moyenne effective inférieure à environ 2 000 nm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38329402P | 2002-05-24 | 2002-05-24 | |
US10/370,277 US20030224058A1 (en) | 2002-05-24 | 2003-02-21 | Nanoparticulate fibrate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27250A1 true MA27250A1 (fr) | 2005-03-01 |
Family
ID=29586821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27964A MA27250A1 (fr) | 2002-05-24 | 2004-11-24 | Formulations de fibrate en nano-particules |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030224058A1 (fr) |
EP (1) | EP1519715B1 (fr) |
JP (2) | JP4395074B2 (fr) |
KR (3) | KR101300654B1 (fr) |
CN (3) | CN101797245B (fr) |
AR (1) | AR040110A1 (fr) |
AU (2) | AU2003301807B9 (fr) |
BR (1) | BRPI0311275A2 (fr) |
CA (1) | CA2487054C (fr) |
EA (2) | EA012842B1 (fr) |
ES (1) | ES2946493T3 (fr) |
IL (2) | IL165332A0 (fr) |
MA (1) | MA27250A1 (fr) |
MX (1) | MXPA04011653A (fr) |
MY (1) | MY143202A (fr) |
NO (1) | NO20050224L (fr) |
NZ (1) | NZ537324A (fr) |
PT (1) | PT1519715T (fr) |
SG (1) | SG159391A1 (fr) |
TN (1) | TNSN04230A1 (fr) |
TW (1) | TWI347198B (fr) |
UY (2) | UY27822A1 (fr) |
WO (1) | WO2004041250A2 (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20030224058A1 (en) | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
AU2003210517A1 (en) | 2002-02-04 | 2003-09-02 | Elan Pharma International, Ltd. | Drug nanoparticles with lysozyme surface stabiliser |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
EP2287166A3 (fr) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés |
BRPI0415121A (pt) * | 2003-10-10 | 2006-11-28 | Lifecycle Pharma As | material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida |
CA2540984C (fr) | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | Forme de dose solide comprenant un fibrate |
US9173847B2 (en) | 2003-10-10 | 2015-11-03 | Veloxis Pharmaceuticals A/S | Tablet comprising a fibrate |
ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
EP1559419A1 (fr) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir |
EP1621200A1 (fr) * | 2004-07-26 | 2006-02-01 | Fournier Laboratories Ireland Limited | Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate |
US20080031825A1 (en) * | 2004-08-20 | 2008-02-07 | Yisheng Chen | Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate |
US7339015B2 (en) * | 2004-10-28 | 2008-03-04 | The United States Of America As Represented By The Secretary Of The Navy | Multifunctional self-decontaminating surface coating |
MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
KR20070118224A (ko) * | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
US20070148233A1 (en) * | 2005-12-28 | 2007-06-28 | Lerner E I | Pharmaceutical formulations of fenofibrate having improved bioavailability |
JP2008534586A (ja) * | 2005-03-30 | 2008-08-28 | テバ ファーマシューティカル インダストリーズ リミティド | フェノフィブレートの改良された製剤 |
MX2007012778A (es) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Formulaciones de derivados de quinazolina nanoparticuladas. |
US20090252807A1 (en) * | 2005-04-13 | 2009-10-08 | Elan Pharma International Limited | Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives |
WO2006084475A2 (fr) * | 2005-04-13 | 2006-08-17 | Lifecycle Pharma A/S | Comprimé comprenant un fibrate |
WO2007036044A1 (fr) * | 2005-09-28 | 2007-04-05 | Dnp Canada Inc. | Combinaison de polychitosamine et de fibrate pour prevenir et traiter l'hyperlipidemie |
US20070148245A1 (en) * | 2005-12-22 | 2007-06-28 | Ilan Zalit | Compressed solid dosage forms with drugs of low solubility and process for making the same |
EP1837020A1 (fr) * | 2006-03-24 | 2007-09-26 | Bioalliance Pharma | Vehicule bioadhesif pour les muqueuses pour delivrer lentement des principes actifs |
JP5508003B2 (ja) * | 2006-06-30 | 2014-05-28 | アイスイティカ ピーティーワイ リミテッド | ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法 |
BRPI0714173A2 (pt) * | 2006-07-12 | 2012-12-25 | Elan Pharma Int Ltd | composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem |
KR100767349B1 (ko) | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 |
US7872560B2 (en) * | 2007-03-19 | 2011-01-18 | Abc Taiwan Electronics Corp. | Independent planar transformer |
PL2200588T3 (pl) * | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
WO2010032434A1 (fr) * | 2008-09-19 | 2010-03-25 | 株式会社アクティバスファーマ | Poudre composite de composés organiques à usage médical, procédé de production de ladite poudre et utilisation de celle-ci |
FR2940118B1 (fr) | 2008-12-24 | 2013-08-09 | Ethypharm Sa | Formulation pharmaceutique de fenofibrate nanonise |
US20110294901A1 (en) * | 2009-01-30 | 2011-12-01 | Shigeru Chikase | Finely pulverized pharmaceutical composition |
AU2010261342A1 (en) * | 2009-06-19 | 2012-01-19 | Sun Pharma Advanced Research Company Ltd., | Nanodispersion of a drug and process for its preparation |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
CN103284952A (zh) * | 2012-02-29 | 2013-09-11 | 北京万生药业有限责任公司 | 一种含有非诺贝特的药物组合物 |
CN103211759B (zh) * | 2013-03-28 | 2015-07-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 葛根素纳米晶药用组合物及其制备方法 |
KR101344218B1 (ko) * | 2013-05-15 | 2013-12-20 | 충남대학교산학협력단 | 페노피브레이트를 함유하는 결핵 치료용 약학 조성물 |
EP3242666A1 (fr) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Procédés de traitement de maladies associées au récepteur s1p1 |
TWI773641B (zh) * | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑 |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
KR101850119B1 (ko) | 2015-11-11 | 2018-04-20 | 제이투에이치바이오텍 (주) | 생체이용률이 향상된 신규한 페노피브르산 전구약물 |
CN105616369A (zh) * | 2016-03-29 | 2016-06-01 | 河北科技大学 | 溶出增强型非诺贝特片的制备方法 |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
US11344535B2 (en) | 2017-06-30 | 2022-05-31 | Kowa Company, Ltd. | Pharmaceutical composition |
KR102081095B1 (ko) * | 2018-04-24 | 2020-02-25 | 한국유나이티드제약 주식회사 | 페노피브릭산 또는 이의 약학적으로 허용 가능한 염을 포함하는 장용성 코팅 정제 |
AU2019287313A1 (en) | 2018-06-11 | 2021-01-07 | Otsuka Pharmaceutical Co., Ltd. | Delamanid-containing composition |
EP3928772A1 (fr) | 2020-06-26 | 2021-12-29 | Algiax Pharmaceuticals GmbH | Composition nanoparticulaire |
KR102369827B1 (ko) * | 2020-09-04 | 2022-03-04 | (주)피알지에스앤텍 | 프로게리닌을 포함하는 나노현탁액 및 이의 제조방법 |
WO2022071768A1 (fr) * | 2020-09-29 | 2022-04-07 | Addpharma Inc. | Composition pharmaceutique comprenant des particules de fénofibrate à biodisponibilité améliorée |
WO2023106447A1 (fr) * | 2021-12-08 | 2023-06-15 | (주)피알지에스앤텍 | Nanosuspension contenant de la progérine et son procédé de préparation |
KR20230114478A (ko) * | 2022-01-25 | 2023-08-01 | (주)피알지에스앤텍 | 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907792A (en) * | 1969-01-31 | 1975-09-23 | Andre Mieville | Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4499289A (en) * | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
AU2317592A (en) * | 1991-07-05 | 1993-02-11 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5545628A (en) * | 1995-01-10 | 1996-08-13 | Galephar P.R. Inc. | Pharmaceutical composition containing fenofibrate |
US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
WO1996025918A1 (fr) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols contenant des dispersions de nanoparticules |
US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (fr) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
FR2761912B1 (fr) * | 1997-04-14 | 1999-07-02 | Capsulis | Procede destine a faire adherer un produit sur une surface |
CA2214895C (fr) * | 1997-09-19 | 1999-04-20 | Bernard Charles Sherman | Composition pharmaceutique amelioree comprenant du fenofibrate |
WO1999029300A1 (fr) * | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Preparations autoemulsifiantes de fenofibrate |
WO1999049846A2 (fr) * | 1998-03-30 | 1999-10-07 | Rtp Pharma Inc. | Composition et procede de preparation de microparticules de substances insolubles dans l'eau |
JP4693238B2 (ja) * | 1998-06-19 | 2011-06-01 | オバン・エナジー・リミテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6383517B1 (en) * | 1999-01-29 | 2002-05-07 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
US6719999B2 (en) * | 1999-03-31 | 2004-04-13 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6465011B2 (en) * | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
JP4156807B2 (ja) * | 1999-06-01 | 2008-09-24 | エラン ファーマ インターナショナル,リミティド | 小型ミル及びその方法 |
US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) * | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
WO2001021154A2 (fr) * | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Compositions particulaires, a surface modifiee, de substances biologiquement actives |
JP5102423B2 (ja) * | 2000-04-20 | 2012-12-19 | オバン・エナジー・リミテッド | 改善された水不溶性薬剤粒子の処理 |
JP4763957B2 (ja) * | 2000-05-10 | 2011-08-31 | オバン・エナジー・リミテッド | メディアミリング |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
ATE424811T1 (de) * | 2000-08-31 | 2009-03-15 | Jagotec Ag | Gemahlene partikel |
AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
US20030224058A1 (en) | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
-
2003
- 2003-02-21 US US10/370,277 patent/US20030224058A1/en not_active Abandoned
- 2003-05-23 WO PCT/US2003/014542 patent/WO2004041250A2/fr active Application Filing
- 2003-05-23 NZ NZ537324A patent/NZ537324A/en not_active IP Right Cessation
- 2003-05-23 CN CN201010144105.6A patent/CN101797245B/zh not_active Expired - Lifetime
- 2003-05-23 CA CA002487054A patent/CA2487054C/fr not_active Expired - Lifetime
- 2003-05-23 MX MXPA04011653A patent/MXPA04011653A/es active IP Right Grant
- 2003-05-23 CN CNA038172704A patent/CN1668281A/zh active Pending
- 2003-05-23 KR KR1020047019041A patent/KR101300654B1/ko active IP Right Grant
- 2003-05-23 BR BRPI0311275A patent/BRPI0311275A2/pt not_active Application Discontinuation
- 2003-05-23 TW TW092114057A patent/TWI347198B/zh not_active IP Right Cessation
- 2003-05-23 PT PT38083630T patent/PT1519715T/pt unknown
- 2003-05-23 EP EP03808363.0A patent/EP1519715B1/fr not_active Expired - Lifetime
- 2003-05-23 SG SG200705850-6A patent/SG159391A1/en unknown
- 2003-05-23 EA EA200401556A patent/EA012842B1/ru unknown
- 2003-05-23 CN CN201010144539A patent/CN101797233A/zh active Pending
- 2003-05-23 IL IL16533203A patent/IL165332A0/xx unknown
- 2003-05-23 EA EA200900485A patent/EA023686B1/ru unknown
- 2003-05-23 JP JP2004549886A patent/JP4395074B2/ja not_active Expired - Lifetime
- 2003-05-23 KR KR1020127012698A patent/KR20120057664A/ko active IP Right Grant
- 2003-05-23 KR KR1020117022782A patent/KR101216853B1/ko active IP Right Grant
- 2003-05-23 AU AU2003301807A patent/AU2003301807B9/en not_active Expired
- 2003-05-23 ES ES03808363T patent/ES2946493T3/es not_active Expired - Lifetime
- 2003-05-24 MY MYPI20031929A patent/MY143202A/en unknown
- 2003-05-26 AR ARP030101837A patent/AR040110A1/es not_active Application Discontinuation
- 2003-05-26 UY UY27822A patent/UY27822A1/es not_active Application Discontinuation
-
2004
- 2004-11-22 IL IL165332A patent/IL165332A/en active IP Right Grant
- 2004-11-23 TN TNP2004000230A patent/TNSN04230A1/en unknown
- 2004-11-24 MA MA27964A patent/MA27250A1/fr unknown
-
2005
- 2005-01-14 NO NO20050224A patent/NO20050224L/no not_active Application Discontinuation
-
2008
- 2008-12-24 AU AU2008264174A patent/AU2008264174B2/en not_active Expired
-
2009
- 2009-08-31 JP JP2009199516A patent/JP2010013462A/ja active Pending
-
2018
- 2018-12-31 UY UY0001038044A patent/UY38044A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27250A1 (fr) | Formulations de fibrate en nano-particules | |
SG161203A1 (en) | Nanoparticulate tacrolimus formulations | |
WO2005002542A3 (fr) | Formulations de meloxicane nanoparticulaires | |
AU2003234452A1 (en) | Nanoparticulate nystatin formulations | |
WO2005013937A3 (fr) | Nouvelles compositions de base libre de sildenafil | |
ATE415946T1 (de) | Neue metaxalon-zusammensetzungen | |
WO2006074218A3 (fr) | Formulations nanoparticulaires de candesartan | |
DE60235411D1 (de) | Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator | |
WO2007059515A3 (fr) | Compositions d'inhibiteurs de lipoxygenase | |
EA200701202A1 (ru) | Препараты из наночастиц бензотиофена | |
ATE422155T1 (de) | Nanopartikelzusammensetzungen enthaltend fenofibrat | |
BR0011030A (pt) | Composições de cicloporina substancialmente livre de óleo | |
WO2007002315A3 (fr) | Formulations de megestrol nanoparticulaire | |
AU2002358027A1 (en) | Coating material containing nanoparticles, use of said coating material and method for the production of coatings | |
EP2263650A3 (fr) | Formulations de mégestrol nanoparticulaire | |
WO2002046342A3 (fr) | Combinaison nettoyante tensioactive constituee de matieres premieres renouvelables a fort pouvoir nettoyant | |
FR2870851A1 (fr) | Nouvelle agent hydrofugeant hydrodispersable, sa preparation et son utilisation dans le domaine de la construction et plus particulierement dans les compositions de liants mineraux | |
WO2005034917A3 (fr) | Poudre d’eau a base de silice hydrophobe | |
WO2003013455A3 (fr) | Formulations cosmetiques et dermatologiques photoprotectrices contenant des derives de benzotriazole et des particules de latex | |
AU2002246211A1 (en) | Solid composition containing at least 75 % by weight of solid particles and at least one non-volatile liquid oil | |
ATE480156T1 (de) | Mineralienzusammensetzung | |
EP1938803A3 (fr) | Formules à méloxicane nanoparticulaire | |
FR2712298B1 (fr) | Composition détergente particulaire à faible teneur en particules fines. | |
FR3112341B1 (fr) | Combinaison detonante, relais pour detonateur comprenant une telle combinaison detonante et detonateur comprenant un tel relais | |
RU2000118398A (ru) | Композиция для получения брикетированного топлива |